Ozempic vs Wegovy: Same Ingredient, Different Purpose — Which One Is Right for You?

You have been living in Bang Tao for eight months. Your Ozempic supply from home ran out two weeks ago. You are not sure whether to reorder the same brand, switch to Wegovy now that weight loss is the main goal, or just walk into a clinic and ask. It is a common situation for long-stay residents and visitors in Phuket who are managing their weight or diabetes without a regular GP back home.

The short answer: both drugs contain the same molecule, semaglutide, but they are approved for different conditions at different doses. One does not automatically replace the other. A physician needs to assess which is appropriate before you start, restart, or switch. Here is what you need to know before that conversation.

Same Molecule, Two Different Jobs, Why Both Brands Exist

Novo Nordisk developed semaglutide first for type 2 diabetes. That became Ozempic, FDA-approved in 2017. Later trials showed the same molecule at a higher dose produced significant weight loss. Novo Nordisk then sought and received a separate FDA approval for weight management under a new brand name, Wegovy, in 2021.

The two brands exist because the approved indications are different. Regulators require separate submissions for separate clinical purposes. They are not interchangeable at a pharmacy counter, and a prescriber must be clear about which condition is being treated.

How the Dosing Works in Ozempic vs Wegovy

Both are weekly subcutaneous injections. Dosing starts low and increases gradually to reduce nausea and other gastrointestinal side effects.

Ozempic starts at 0.25 mg weekly, moves to 0.5 mg, then 1.0 mg, with a maximum approved dose of 2.0 mg weekly. Wegovy follows a longer escalation: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, then a maintenance dose of 2.4 mg. That full escalation takes approximately four months, with each step lasting four weeks before the maintenance dose is reached.

The higher ceiling on Wegovy matters. The weight loss trials used 2.4 mg. Capping at 2.0 mg means you are not reaching the dose that produced the published results.

Who Actually Qualifies, Diabetes, BMI, and Assessment Criteria

Ozempic is indicated for adults with type 2 diabetes. It is also approved to reduce the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease.

Wegovy is approved for adults with a BMI of 30 or above, or a BMI of 27 or above with at least one weight-related health condition present, such as high blood pressure, high cholesterol, or type 2 diabetes. It is also approved for adolescents aged 12 and over with obesity, based on age and weight criteria assessed by a physician.

If you have type 2 diabetes and want to lose weight, both drugs are potentially relevant. That overlap is exactly what a physician needs to work through with you. Off-label prescribing of Ozempic for weight loss does happen, and a prescriber may consider it where Wegovy is unavailable or cost is a factor. That decision requires individual clinical assessment, not a self-referral.

What the Clinical Trials Actually Showed

For diabetes, Ozempic has strong evidence for reducing HbA1c, your average blood sugar level over roughly three months. It also has proven cardiovascular benefit in people with type 2 diabetes and existing heart disease.

For weight loss, the STEP 1 trial tested semaglutide at 2.4 mg and showed an average body weight reduction of around 15 percent over 68 weeks in adults without diabetes, alongside lifestyle changes. Wegovy also has evidence from the SELECT trial showing reduced major cardiovascular events in adults with obesity and existing cardiovascular disease but without diabetes. That is a clinically meaningful finding for older expats with cardiac risk factors.

The weight loss evidence is specific to 2.4 mg. Using Ozempic off-label at 2.0 mg may produce meaningful weight reduction, but the trial data supporting that average loss used Wegovy at its full approved dose.

Side Effects to Expect, Especially Mid-Trip in Phuket

The most common side effects are nausea, vomiting, diarrhoea, constipation, and stomach discomfort. These tend to be worse during dose increases and settle as your body adjusts.

If you are in Karon or Kata and you have just stepped up to a new dose, nausea on day two or three is common. Eating smaller meals, avoiding fatty or spicy food, and staying hydrated helps. Persistent vomiting that stops you keeping fluids down is a reason to get assessed. Severe dehydration in Phuket’s heat progresses faster than people expect, especially if you are also spending time in the sun.

Less common but more serious: pancreatitis, which presents as severe persistent abdominal pain radiating to the back, and gallbladder problems. There is also a possible increased risk of thyroid tumours based on animal studies, which is why semaglutide is contraindicated in people with a personal or family history of medullary thyroid carcinoma. Any prescribing consultation should cover these points before you start.

Practical Considerations for Travellers and Expats in Phuket

Storage matters here. Both pens must be refrigerated at 2 to 8 degrees Celsius when not in use. An in-use pen can be kept below 30 degrees Celsius: Ozempic for up to 56 days, Wegovy for up to 28 days, per their respective product labels. In Phuket’s heat and humidity, a pen left in a hotel room without air conditioning, a car glove box, or a beach bag in direct sun can breach that threshold quickly. A small cool bag with an ice pack is a simple fix. Never use a pen that has been frozen.

If the missed dose was due within the past five days, take it when you remember and continue on the usual schedule. If more than five days have passed since the missed dose, skip it and resume the following week. Missing two or more consecutive weeks may mean stepping back down in dose when you restart. That is worth discussing with a prescriber before a liveaboard trip or a long stretch in the outer islands where refrigeration is unreliable.

If you are travelling to Thailand carrying semaglutide, bring the original prescription, keep pens in carry-on luggage, and carry a letter from your prescribing physician. This protects the cold chain and avoids questions at customs. If your supply runs out or a pen is damaged while you are here, a prescription refill in Phuket is possible with a physician assessment.

Getting Semaglutide in Phuket, What the Physician Assesses

Semaglutide is a prescription medication in Thailand and is not dispensed without one. A walk-in assessment at Takecare Clinic Phuket covers the key eligibility criteria: your BMI, current medications, relevant medical history, and which indication applies.

The physician will check for contraindications: history of pancreatitis, thyroid cancer in yourself or a close family member, pregnancy or planned pregnancy, and any medications that interact with semaglutide. If you are already on a dose from a prescription at home and need continuity, bring your pen and any documentation you have.

Semaglutide is not a set-and-forget medication. Blood pressure, blood sugar if diabetes is a factor, and your general response to the dose are worth monitoring over time. A blood test in Phuket can check the relevant markers if it has been a while since your last review. For residents managing ongoing conditions from Chalong to Surin, walk-in physician care with English-speaking doctors in Phuket means you do not need to travel to Phuket Town or wait for a hospital appointment for a medication review. If you want to work through which semaglutide is right for me before your visit, a physician can walk through the clinical decision with you.